PRARAM 9 HOSPITAL PUBLIC COMPANY LIMITEDSET: PR9🇹🇭 TH

Board Performance · 2024

Compliance Monitoring — Overview

Monitoring of Compliance with Other CG Policies & Guidelines

Monitoring and handling procedures when receiving information, complaints, or reports of wrongdoing

In 2024, the Company did not receive any information about any wrongdoings resulting from corruption. The Risk Management Manager has summarized the report to the Audit Committee meeting every quarter. However, the Company has communicated to executives and employees to be aware of the regulations, practices, including the anti-corruption policy and penalties, in addition to training new employees on the employee orientation day and reviewing it regularly every year.

Prevention of Conflicts of Interest

Has the Company Acted to Prevent Conflicts of Interest?

Yes

Operations in the Past Year

Prevention of Conflicts of Interest

The Company has established a policy and practice guidelines on the prevention of conflict of interest based on the principle that any decision on business activities shall be done for the best interests of the Company and shareholders and shall avoid actions that cause conflict of interest to ensure fairness to all stakeholders. The Company, therefore, sets a policy to prevent exploitation of personal interests from being a director, executive or employee of the Company. As a result, the Company has determined practices for directors, executives and employees of the Company as follows:


Practices to prevent conflicts of interest.

(1) Avoid conducting related party transactions or connected transactions with oneself or related persons that may cause conflict of interest with the Company, except for transactions that will support medical services and/ or transactions that are reasonable and create benefits to the Company.

(2) Refrain from seeking own benefits or benefits of others by using and disclosing information or internal information that has not been disclosed to the public or is confidential to outsiders.

(3) Not use documents or information obtained from being the Company’s director, executive or employee in doing his/her own business or other persons’ business that is in competition to or having common characteristics or related to the Company’s business.

(4) In case a conflict of interest is found, the matter shall be reported immediately to the supervisor.

The Company has communicated the conflict-of-interest prevention policy to Directors, executives and employees through various communication channels, such as on orientation day, Intranet, and the Company’s documents, and organizes an annual training for review.

In the past year, the internal auditor reviewed the operational process and found that the implementation of the aforementioned persons and departments completely met the policy requirements. In addition, no violations or wrongdoing arising out of a conflict of interest was found.

Number of Conflict-of-Interest Cases

MetricCurrent YearPrevious YearTwo Years Ago
Total number of cases or issues related to conflicts of interest (cases)000

Prevention of the Use of Inside Information

Has the Company Acted to Prevent the Use of Inside Information?

Yes

Operations in the Past Year

Use of inside information for personal benefits

The Company places importance on the supervision of the use of internal information and confidentiality, maintenance of information and confidential documents of customers, and information security in the information technology system. The Company shall not publicly disclose or release confidential information and documents as well as unpublished internal information for own and others’ direct or indirect benefits and with or without returns. The Company’s securities shall not be traded using confidential information and documents or internal information, unless it must be disclosed as required by law. The Company has therefore established a policy on the use of information and confidentiality as guidelines for keeping and preventing the use of internal information that may be significant and may affect the changes in the Company’s stock price as follows:


Practices to prevent the unauthorized use of internal information and maintain confidentiality.

(1) Prohibit individuals or units that perceive internal information to disclose such information to unrelated individuals or units unless the Company has already publicly disclosed such information

(2) Directors, executive directors, employees and staff members, including advisors to the Chief Executive Officer, who have acknowledged significant internal information which has or may have an effect on the price of the Company’s securities as well as financial information, shall refrain from trading of the Company’s securities during the 30-day silence period prior to the disclosure of financial statements or internal information to the public and during the 24 hours after the Company’s information has been publicly disclosed. Those related to such information shall not disclose that information to other persons, unless such information has been notified to the SET. (3) Doctors, consultants and staff members who play significant roles must sign a non-disclosure agreement to protect the Company’s business information, trade information and confidential information.

The Company has disclosed a policy on the prevention of the use of internal information and confidentiality on the Company’s website, www.praram9.com, for all directors, executives and employees to acknowledge and use as practice guideline. The Company has also included the policy in the orientation program for new employees. In the past year, there was no insider trading case.


Policy on Securities Trading and the Use of Inside Information

The Company has a policy to comply with the law regarding the use of internal information, ensuring fairness and impartiality to all shareholders equally, and to prevent any unlawful activities. Therefore, the Company has established practices as follows:


Practices to prevent insider trading of the Company's securities.

(1) Directors, executives and auditors of the Company which issues securities are obliged to disclose and report of their securities holding, their spouses or partners as well as minor children, juristic person in which they, their spouses or persons living together as husband and wife, and minor children holding more than 30 percent of the total voting rights of the juristic person, according to the regulations of the SET and the SEC

(2) Employees at all levels of the Company, as well as their families who have knowledge or may have access to non-public information, are prohibited from engaging in the buying or selling of the Company stocks, or encouraging others to buy, sell, offer to buy, or offer to sell the Company's stocks, either personally or through agents, while in possession of undisclosed information. The Company and the Stock Exchange of Thailand consider such securities transactions as trading for profit or benefiting a particular group. Therefore, directors, executives, employees, and contractors of the Company, including advisors with access to significant non-public information that may impact changes in the Company's stock prices, must refrain from trading the Company's stocks within the 30 day period prior to the disclosure of financial statements or internal information to the public. This restriction applies within the 24 hours following the public disclosure of such information by the Company.

(3) The Company has established a security system in the workplace to safeguard files and confidential documents. The Company has also restricted access to non-public information by providing only to necessary and related persons. This is considered the duty of the information owner or the person who possesses the non-public information to urge those involved to strictly follow the security procedures.

Violators of the use of internal information shall be subjected to disciplinary actions and/or laws, as the case may be, ranging from verbal warning, written notice, probation and termination.


Support from the Company’s Secretary

With regard to the internal operations, the Company Secretary shall inform the Directors, executives and concerned employees of the blackout period and the schedule of the Board of Directors’ Meeting and the annual general meeting of shareholders one year in advance.

In addition, around five days prior to each quarterly meeting, the Company Secretary shall inform the Directors, executives, management, employees, staff members and advisors who receive material inside information that could influence any changes in the Company’ s security price of the blackout period by email in order to prevent insider trading.

In the past year, none of the persons mentioned above traded the Company’s securities within 30 days before the financial statements and inside information were publicly disclosed, and 24 hours after they are publicly disclosed.

Number of Inside-Information Cases

MetricCurrent YearPrevious YearTwo Years Ago
Total number of cases or issues related to the use of inside information to seek benefits (cases)000

Anti-Corruption

Has the Company Acted on Anti-Corruption?

Yes

Operations in the Past Year

Anti-Fraud and Corruption Policy

The Company adheres strictly to the transparency, ethics, and good governance, and complies fully to the laws related to anti-fraud and corruption and bribery of government officials or private sector. The Company has created organizational structure that clearly segregates responsibilities, operational processes and line of command to ensure balance of power and appropriate cross-audits. The Company also clearly sets good practice guidelines for Directors, executives and employees in anti-fraud and corruption as follows:


Practices to prevent involvement in corruption and collusion.

(1) Prohibit Directors, executives and employees from direct and indirect practices or accept fraud and corruption in all forms. This applies to all related organizations. A regular monitoring and review of the anti-corruption policy is implemented to best address the changing rules, regulations and legal requirements. (2) Directors, executives and employees hold the responsibility to report to the Company on all fraud and corruption related practices by informing their immediate supervisors or responsible persons and shall cooperate in fact finding activities.

(3) The Company shall fairly treat and protect whistleblowers who report information about fraud and corruption to the Company as well as those who cooperate with the Company in the fraud and corruption investigation process.

(4) The Board of Directors and executives shall act as a role model in fighting against fraud and corruption and encourage and promote anti-fraud and corruption policy by communicating with employees and all related parties, reviewing the appropriateness of related policies and measures to better address the changing business environment, rules, regulations and legal requirements.

(5) Those involved with fraud and corruption shall be subject to disciplinary actions in accordance with the regulations set by the Company and may be subject to legal actions if an illegal act is committed.

(6) The Company arranges training and disseminates knowledge and information to Directors, executives and employees to ensure their understanding of anti-fraud and corruption policy and to promote ethical practices, integrity, responsibility and their own duties.

(7) The Company encourages its counterparties, trade partners and other persons performing duties that are related to the Company’s operations to report on the infringement of the Company’s anti-fraud and corruption policy.

(8) The Company has a policy to fairly and adequately nominate and select persons, promote, train, assess performance, and determine remuneration of its employees and contractual staff to prevent fraud and corruption within the organization and provides employees and contractual staff with security.

(More information is presented in “Anti-Fraud and Corruption Policy” in the Corporate Governance, Attachment 5 and on the Company’s website at https://investor.praram9.com/th/company-info/corporate-governance/corporate-governance-policy)


Gift Giving and Receiving Policy

To support and prevent a loophole that may lead to corruption, the Company has clearly determined the gift giving and receiving policy as follows:


Practices regarding the giving and receiving of gifts by the Company.

(1) Directors, executives or employees shall not ask for, receive or accept to receive money or other benefits from those with related businesses.

(2) Directors, executives or employees may receive or give gifts according to the tradition. The gift shall not worth over 3,000 baht (Three thousand Baht). In case the value exceeds 3,000 Baht (Three Thousand Baht), the person shall report to their immediate supervisor. Accepting gift shall not have impact on any business decision of the receiver.


Fraud and Corruption Risk Assessment

The Company has prepared risk management plan three years in advance and regularly reviews, adjusts the risk management framework every year and clearly identify responsible persons.

The key essence of the Risk Management Plan (2021-2023) centers around sustainability, opportunity and performance, and ERM Certify. The Company has clearly set criteria for risk assessment, both likelihood and potential impact, to cover all risks that are not medical treatment related.


Fraud and Corruption Risk Assessment

Fraud and corruption risks arising from business operations and reputation risk are among the six possible risks, such as financial report preparation, loss of assets and corruption. The Company has prepared risk management guidelines as follows:

(1) Establishing the Risk Management Committee, comprising Directors and senior executives, to formulate enterprise risk management policy. The Chairman of the Risk Management Committee is a Director/ the Chief Executive Officer, who is the top executive of the Company.

(2) Realizing the importance of systematic, efficient and timely risk management, the Risk Management Committee reports directly to the Audit Committee to determine direction, measures, action plan, policy and risk management framework that are in line with the Company’s risk management policy.

(3) Monitor, assess and ensure the Company’s risk management is in line with its corporate strategic plan and business direction. It shall also cover policy and scope of the management of the Company’s risks arising from external and internal factors.


In addition, the Company has an internal control and audit system according to the regular annual audit plan. The Internal Audit, which is independent and does not report directly to the management, shall review risks, internal control, corruption and/or related processes and report the results to the Audit Committee and the Board of Directors for consideration respectively.


Internal Audit against Fraud and Corruption

(1) The Company has put in place the internal control system to handle corruption related matters, covering the areas of financial, accounting and record keeping, as well as other processes related to anti-fraud and corruption.

(2) The internal control system is established to ensure reasonable confidence that the Company’s operations is efficient, reliable and compliant to anti-fraud and corruption related regulations and policy determined by the Company.


Supervision and Control to Prevent and Monitor Fraud and Corruption Risk

The Company has established practice guidelines for supervision and control to prevent and monitor the fraud and corruption risk as follows:

(1) Directors and executives are responsible for preventing and detecting fraud and errors by continuously introducing sufficient accounting system and internal control system. Directors and executives at all levels shall perform their duties with honesty, integrity, ethics and morality.

(2) The Company will provide risk management that covers the identification and consideration of risks, assessment of the impacts of such risks, consideration on control activities, including monitoring, internal control, and risk response methods covering monitoring of prevention capability, and detecting fraud, errors and failure to comply with laws.

(3) Arrange for an internal control system in terms of prevent control and detective control, which is a tool to reduce chances and incentives for misconduct and corruption. The Company has established the criteria for the segregation of duties, such as the segregation of duties between the procurement unit from the finance and accounting unit. In addition, the Company has in place monitoring and assessment processes where the executives will receive reports and acknowledge the causes of the defects or suspicious situations in a timely fashion as well as be able to appropriately improve the preventive control system in assessing internal control. The Internal Audit Department acts as part of the process.


Monitoring and Assessment of Anti-Fraud and Corruption Policy Implementation

The Company has set guidelines for monitoring and assessing the implementation of the anti-fraud and corruption policy as follows:

(1) Entrust the Audit Committee to review the accuracy of reference documents and self- assessment form regarding the Company’s anti-corruption measures and approve the Company’s assessment report on corporate governance and corporate social responsibility and anti-fraud and corruption

(2) Directors, executives and employees of the Company shall report to the Company on the actions that are considered corruption related to the Company by notifying the supervisor or responsible persons and cooperate in examining the facts.

(3) The Board of Directors and executives of the Company shall behave as a role model in anti-corruption to communicate to all employees and related parties and review the policies and measures to ensure they are appropriate and best address the changing business environment, regulations and legal requirements.

(4) Directors, executives and related persons shall provide risk management that covers the identification and consideration of risk factors and monitor the process of internal control and risk response, including monitoring the assessment of ability to prevent and detect fraud, error and compliance or non-compliance with the regulations.

The Company ensures communication of such guidelines through various channels such as the Company’s Intranet and website, www.praram9.com, for executives and all employees for acknowledgement and compliance.


Employee Training on Anti-Fraud and Corruption Policy and Guidelines

1) Employee orientation and training programs and seminars during the year.

The Company includes employee training on ethics and practice guidelines in the orientation program. The training content will be reviewed during the year every year and included as part of the corporate governance and social responsibility training courses. Key policies are as follows:

· Anti-fraud and corruption policy and practice guidelines

· Protection of employees who report clues about fraudulent conduct, or failure to comply with laws, regulations and the Company’s Articles of Association.

· Giving or receiving gifts or entertainment

· Prevention of conflicts of interest

· Insider trading

· Protection of the Company’s confidential information

· Internal control and audit system

· Financial and accounting reporting

· Responsibility toward shareholders

· Treatment of executives and employees

· Behaviors of executives and employees

All employees have to complete certain training hours as required by the Company and have to achieve 100 percent score test. In case of failing to pass the test, the Company provides an opportunity for them to study and review their knowledge and understanding before retake the test until they pass.

2) Communication The company has communicated to all employees in the organization through various channels, such as the internal computer network system (Intranet), announcements at important points within the company, employee LINE groups in the organization, and has also published to external parties on the company's website at www.praram9.com, Investor Relations section.


Cooperation to adopt the Company’s anti-fraud and corruption policy and measures.

The Company has realized the importance of transparency in business operations and anti-fraud and corruption practice. In addition to campaigning and encouraging employees to fight against corruption, the Company informed in writing, requesting cooperation from trade partners, business partners, and related persons and/or organizations to fight against corruption by following the practice guidelines published within and outside the Company via its website: www.praram9.com under Corporate Governance section in About Us menu. Should the persons intend to cooperate with the Company, the persons should send back to the Company the Confirmation Form in support of the adoption of the Company’s anti-corruption policy and measures.

Persons who encounter corruption within the Company can report the information, complaints or clues to the Company by sending a letter to the Audit Committee, or via telephone or the Company’s website.

Form of Anti-Corruption Operations

Operation
Review of the completeness and adequacy of the process by the Audit Committee or auditor
The monitoring of the evaluation of compliance with the anti- corruption policy
Communication and training for employees on anti-corruption policy and guidelines
Review of appropriateness in anti-corruption
The participation in anti-corruption projects
Assessment and identification of corruption risk

Number of Corruption Cases

MetricCurrent YearPrevious YearTwo Years Ago
Total number of cases or issues related to corruption (cases)010

Details of Corruption Cases

StatusPeriod TypeStart of PeriodEnd of PeriodDetails of the Case or IssueInvestigation ResultsCorrective Actions
Incident no longer subject to actionmonth/year Range2023-092023-10
In the year 2023, the Company received information regarding an act of misconduct rerate to the misappropriation of Company assets by one employee. The incident was associated with company assets used in the course of duty. The Company took appropriate actions in accordance with internal policies and procedures to address this case of corruption. Furthermore, the matter was reported to the Audit Committee during the 4/2023 on 8 November 2023 and the Board of Directors Committee during the 6/2023 on 9 November 2023, respectively. However, to prevent such issues from recurring, the Company has communicated with executives channels to raise awareness and ensure understanding of the rules, practices, anti-corruption policies, and penalties. This communication includes regular training foe new employees during the orientation day and periodic reviews conducted annually.
Completed
The Company took appropriate actions in accordance with internal policies and procedures to address this case of corruption

Whistleblowing

Has the Company Implemented Whistleblowing Procedures?

Yes

Operations in the Past Year

Whistleblowing

The Company has the policy to protect and ensure fair treatment to directors, executives and employees who report the information or provide clues on corruption or non-compliance with the laws, regulations, Articles of Association of the Company as well as the Code of Business Conduct (Whistleblower Policy) which are as follows:

Method of complaint and misconduct report filing

(1) The complainant shall directly send complaints or clues of the wrongdoing and fraud in writing to the responsible supervisor (from manager level up). However, in a situation where it is not appropriate or inconvenient, the complainants can report via the Company’s Intranet system, e-mail, comment box or send a letter to the Manager of Quality Department.

(2) The supervisor who receives a complaint or clue of wrongdoing and corruption shall notify the Manager of Quality Department without delay or within three working days, to proceed with the investigation process.

(3) In the event that the complainant chooses not to disclose the name, the complainant shall clearly specify facts or sufficient evidence to prove that there is a reason to believe that there is fraud or violation of laws, regulations and Articles of Association of the Company or the Code of Business Conduct of the Company.


Fact finding process

(1) In conducting an investigation and collecting facts, the complaint recipient shall present the complaint to the following persons (“Inspector”) for inspection and fact collection related to the complaint.

(1.1) In case where the person being complained is an employee in the level lower than executive, the Deputy Managing Director and/or the persons or units assigned by the Deputy Managing Director to act as the inspector.

(1.2) In case where the person being complained is an employee in executive level and higher, the Audit Committee and/or the persons or units assigned by the audit committee to act as the inspector.

In case where there are inquiries or questions, the inspector can invite any employee or supervisor who is directly responsible for the complainant to provide information or request to send any documents related to the investigation.

(2) If the inspection shows that the complaint is true, the Company shall proceed within seven days as follows:

(2.1) In the case of complaints related to fraudulent acts or non-compliance with the laws or regulations, Articles of Association or Code of Business Conduct, the inspector shall consider proposing such complaint along with opinions to the Audit Committee for further consideration

(2.2) The inspector shall inform of the progress and results of the investigation on complaint on misconduct and corruption to the complainant who has provided name, address, telephone number, email or other contact information. However, in some cases and for privacy and confidentiality of personal information, the Company may not be able to provide detailed information of the investigation or disciplinary action.

(2.3) In case where such complaint is significant, such as the matter that affects the reputation, image or financial position of the Company, conflict with the Company’s business policy or related to high-level executives, the inspector shall consider proposing the said matter with comments to the Board of Directors for further consideration.

(2.4) In case where the complaint causes damage to any person, the inspector shall propose appropriate and fair measures to mitigation such damage to the victims under the framework set by the Board of Directors and/or the Audit Committee.

(2.5) The Internal Auditor shall find the cause and solutions to the misconduct or wrongdoing in order to prevent reoccurrence and shall report to the Audit Committee for acknowledgement and implementation of the solution.


Safeguarding the whistleblower

(1) The complainant can choose not to reveal oneself if he/she feels that the disclosure may cause damage. However, the complainant shall specify clear and sufficient details of facts or evidence proving that there is a reasonable cause to believe of such fraudulent act or violation of laws, rules, regulations and Articles of Association of the Company or Code of Business Conduct. However, if the complainant chooses to reveal oneself, the complaint recipient will be able to proceed faster.

(2) The Company considered the information related to the complaint as confidential and will disclose only as necessary considering safety and damage of the whistleblower, source of information or the related persons. The person responsible in all procedures shall keep the information at the highest level of confidentiality and shall not disclose it to others. Violation of such practice will be considered a violation of discipline.

(3) In case where the whistleblower considers that he/she may be insecure or troubled or damaged, the complainant can request the Company to provide appropriate protection measures or the Company may establish protection measures without receiving request by the whistleblower if it considers that the matter is likely to cause damage or insecurity.

(4) Employees who treat other people with unfair manner, discrimination or cause damage to other persons who report or complain or provide clues on corruption or non-compliance with laws, rules, regulations or business ethics of the Company, or file a lawsuit or be a witness or give statements or cooperation to the court or government organizations, the employees shall be considered performing and offense of discipline and shall be punished. Such persons may be punished as specified by law if the persons commit offense under the law.

(5) Those who have suffered or damaged will be compensated through appropriate and fair methods and process considered by the Quality Department.


In addition, external stakeholders can ask for information, report complaints or clues of illegal acts, inaccuracy of financial reports, defective internal control system or violation of the Company’s Code of Business Conduct or violation of rights through the complaint channels as follows :

(1) By mail : The Audit Committee Rama 9 Hospital Public Company Limited No. 99 Rama IX Road, Bangkapi, Huai Khwang, Bangkok 10310

(2) By phone: 1270

(3) The Company’s Website, www.praram9.com, under the Investor Relations Section, on the Whistleblowing Page.

(4) The Company’s Website, www.praram9.com, on the Contact Us Page for submitting suggestions, feedbacks, questions or complaints

(5) Public Relations Signage by scanning the QR Code on the signage to submit suggestions, feedbacks, questions or complaints.


The information, complaints and clues of misconduct that are reported to the Company will be kept confidential. The Audit Committee shall command for the inspection of information to find solutions and shall further report to the Board of Directors.


Protection of Directors, Executives and Employees

(1) The Company assures Directors, executives and employees that they will not be demoted, punished or affected when they refuse to take bribery even though such action causes the Company to lose business opportunity. The Company believes that the anti-corruption and bribery policy and practices would create long-term value for the Company. The Company does not allow anyone to threaten, harass or detain Directors, executives and employees who are committed to anti-corruption policy

(2) In case a Director, executive or employee believes he/she is threatened, harassed or detained, the person should immediately report the clue or file a complaint to the supervisor or the Human Resource Department. If the case is not being attended properly, the person shall report through the Company’s reporting channels.

Number of Whistleblowing Cases

MetricCurrent YearPrevious YearTwo Years Ago
Total number of cases or issues received through whistleblowing channels (cases)000

Selection of Directors & Chief Executives

Are Directors Selected Through the Nomination Committee?

Yes

Are Chief Executives Selected Through the Nomination Committee?

Yes

Rights of Minority Shareholders on Director Appointment

The Company has a policy to allow shareholders to propose additional agenda and nominate qualified persons to be elected as the Company’s directors at the Annual General Shareholders’ Meeting. This includes the opportunity for shareholders to submit questions on the Company or about the agenda in order to inquire on doubtful issues to the Company in advance, prior to the Company’s Annual General Shareholders’ Meeting. The Company has published details and criteria for granting such right on the Company’s website at www.praram9.com under the Investor Relations section and on the SET’s website for acknowledgement of shareholders and investors. Details are as follows:


Proving the shareholders with the right to propose additional agenda, nominate qualified persons to be elected as directors, and submit questions prior to 2024 Annual General Meeting of Shareholders

- Meeting date 23 April 2024 (via electronic means)

- Providing the right to propose additional meeting agenda and nominate person to be elected as director 1 October 2023 - 31 December 2023

- Providing the right to submit questions prior to the meeting 1 October 2023 – 31 March 2024

Note: No shareholders proposed additional agenda items, nominated individuals for election as directors, or submitted advance questions.


A for the 2025 Annual General Meeting of Shareholders, the Company provided shareholders with the opportunity to propose additional agenda and nominate qualified persons to be elected as the Company’s directors in advance, starting from 1 October 2024 to 31 December 2024. Shareholders can submit questions about the Company prior to the meeting from 1 October 2024 to 31 March 2025.


Voting, vote counting, and vote counting method in each agenda: The Company provided ballots for every agenda. On the agenda concerning the appointment of Directors, the Company provided shareholders with an opportunity to vote for each individual nominated candidates for the appointment of Directors by using advanced technology for shareholders’ convenience, and for faster and more accurate vote counting in order to enable the Company to present the vote counting results to the shareholders for prompt acknowledgement as follows:

(1) In case of physical meeting, barcode system will be adopted;

(2) In case of e-Shareholder Meeting, e-Proxy system will be adopted.

In 2024, the Company conducted an e-Shareholder Meeting, however the shareholders were able to vote for each individual nominated candidate for the appointment of Directors. In order to comply with the relevant laws and the Company’s Articles of Association

Method of Director Appointment

Method
Method whereby each director requires approval votes more than half of the votes of attending shareholders with voting rights

Selection of Independent Directors

Criteria for Selecting Independent Directors

Independent Director

Of the total number of members of the Board of Directors, at least one third or no less than three persons must be independent directors, according to the Company’s Good Corporate Governance and Business Code of Conduct Handbook. All independent directors shall be knowledgeable, competent and qualified as prescribed by the laws, by being able to independently express opinions in the meeting, regularly attend the meetings and have adequate access to other financial and business information to be able to express opinions independently, maintain the benefits of related persons and prevent conflicts of interest between the Company and directors, executives or majority shareholders or other companies that have the same group of directors, executives or majority shareholders. Moreover, independent directors shall report their independence once appointed and on yearly basis, which will be disclosed in the Annual Report and notified to the Company for acknowledgement of changes.

The Company has established the following qualifications of independent director:

(1) Holding no more than one percent of total voting shares of the Company, its parent company, subsidiaries, associated company, major shareholders or controlling persons, inclusive of the shares held by related persons of such independent director.

(2) Not being or used to be an executive director, employee, staff, advisor with regular salary, or controlling person of the Company, its parent company, subsidiary, associated company, subsidiary of the same level, major shareholder or controlling person unless the person has retired from having such characteristics for at least two years prior to the appointment as independent director. Such prohibited characteristics, however, do not include the case that the independent director used to be a government official or advisor of a government agency which is a major shareholder or controlling person of the Company.

(3) Not being related, whether by blood or legal registration as father, mother, spouse, sibling and child, including spouse of the offspring of other directors, executives, major shareholders, controlling parties, or persons who will be nominated as directors, executives, or controlling parties of the Company or subsidiary.

(4) Not having or never had any relationship with the Company, its parent company, subsidiary, associated company, major shareholder or controlling person, in the manner that may prevent the person to have independent judgement. The person should not currently be or never be a significant shareholder or controlling person of any person having a business relationship with the Company, its parent company, subsidiary, associated company, major shareholder or controlling person, unless the person has retired from having such characteristics at least two years before the appointment as an independent director.

(5) Not being or having never been the auditor of the Company, its parent company, subsidiary, associated company, major shareholder or controlling person and not being a significant shareholder, controlling person, or partner of an audit firm which employs auditors of the Company, its parent company, subsidiary, associated company, major shareholder or controlling person; unless the person has retired from having such characteristics at least two years before appointment as an independent director.

(6) Not providing or having never provided professional services, legal consulting, nor financial consulting services and received fees exceeding two million Baht per year from the Company, its parent company, subsidiary, associated company, major shareholder or controlling person, and not being a significant shareholder, controlling person or partners of the such services providers unless the person has retired from having such characteristics at least two years before appointment as an independent director.

(7) Not being a director appointed as a proxy of the Company’s director, major shareholder, or a shareholder with relationship with a major shareholder

(8) Not undertaking any business of the same nature and in competition with the business of the Company or the Company’s subsidiary, or not being a significant partner in a partnership nor an executive director, employee, staff, advisor with regular salary or holding shares exceeding one percent of the total number of shares with voting rights of another company which operates a business of the same nature and in competition with the Company or its subsidiary

(9) Not possessing any other characteristics that prevent the ability to independently express opinions on the Company’s business operations.


Recruitment and Appointment of Directors, Board Executives, and Senior Management

Criteria for Considering the Appointment of Directors, Board Executives, and Senior Management

(1) The Nomination and Remuneration Committee is responsible for considering and nominating directors, sub-committee, and the Company’s Chief Executive Officer, who have complete qualifications and meet with the Company’s director qualification guidelines (More details of the qualifications of directors and the Chief Executive Officer are presented under the “Management Structure” Section, “Qualifications of Directors, Independent Directors and the Chief Executive Officer”), and have the knowledge, capabilities, and experience that support the business strategy. The nominee shall be able to contribute sufficient time to perform the duties as a director, and has necessary skills currently lacked in the Board Skill Matrix. The committee will then carry out the director and executive appointment process.

(2) In case a shareholder nominates a person with appropriate qualifications as a director and/or the Chief Executive Officer, the Nomination and Remuneration Committee shall consider the qualifications of the nominated person according to the Company’s criteria and continue the director and senior executive appointment process.


The Company places importance on Board diversity for effective, flexible, and beneficial management which can lead the Company to achieve the main objectives and goals. For this reason, the Company has established the policy on the diversity of structure of Board of Directors as follows.

(1) The structure of the Company’s Board of Directors is consistent with the Company’s Articles of Association which prescribes that the Board of Directors shall have not less than five (5) persons. Not less than half of the total number of directors shall have residence in Thailand and shall have all the qualifications required by the Company’s Charter as well as shall not be a person with prohibited qualifications as required by law. The shareholders will consider the appointment of the Company’s directors

(2) The number of independent directors shall be no less than one third of the total number of the directors and shall not be less than three (3) persons, including at least two (2) female independent director to provide opportunities and increase the role of knowledgeable and capable women to demonstrate and bring out their capabilities and experience to develop the organization.

At present, there are two female directors, representing 20 percent of the total 10-member Board of Directors. Having female directors sitting in the Board will add diverse and sensitive opinions that provides more balanced opinions in any consideration and discussion.

In the future, if the Company increases the number of directors, the Company has a policy to provide equal opportunity for new male and female directors and fully support any additional female independent directors.

(3) The Board of Directors shall consist of persons with knowledge, capabilities and skills and a variety of expertise (Board Diversity), performing their duties in an ethical manner and with integrity, and having experience related to the Company’s business that supports the performance of their duties to enable the composition of the Board of Directors to be in accordance with the Company’s short-term and long-term business strategies, regardless of gender, age, race, religion, educational background, knowledge and professional skills.

In the recruitment and appointment of the board, the Company considers diversity in the board structure (Board Diversity) in various aspects as appropriate. The composition of the board (please refer to Section 7.2 for details on board composition, Section 7.2.1 Board of Directors) and details of knowledge, expertise, and specialization (Board Skill Matrix)

(4) The Chairman of the Board of Directors is not an individual who is also an executive director and is not a member of any sub-committees to ensure that sub-committees can express their opinions independently.

(5) The Board of Directors consists of 4 directors with experience in the medical field, consisting of 3 executive directors, accounting for 30 percent of the total Board of Directors, and 1 independent director, accounting for 10 percent of the total Board of Directors.

(6) The Board of Directors has a tenure of not more than three years in accordance with the specifiedlaws. The Board of Directors has established the policy specifying that the tenure of an independent director shall not exceed nine consecutive years from the first day of appointment as independent director and without any exemption.

(7) To ensure the Company’s proper and smooth management, the Company has appointed a Vice- Chairman of the Board of Directors to perform the duty in case where the Chairman of the Board of Directors is not able to attend a meeting. The Board of Directors resolved to appoint Dr. Satian Pooprasert to be a Vice-Chairman of the Board of Directors.


The process for recruiting and appointing directors, executive directors, and senior executives.

(1) In the nomination and appointment of directors and the Company’s the Chief Executive Officer is partly based on Professional Search Firm or the Director Pool to create diversity in the structure of the Board of Directors.

(2) Prepare Board Skill Matrix to determine the qualifications of directors that the Company wants to recruit, by considering the necessary skills the Board of Directors still lacks of and work experience that is in alignment with the Company’s business strategy.

(3) In case where the Nomination and Remuneration Committee considers that the Company still lacks of the directors or executives who have specific knowledge, competency or specific experience, the Nomination and Remuneration Committee will consider recruiting persons for additional positions to comprehensively help develop work potentials in various aspects of the Company.

(4) Once the Nomination and Remuneration Committee has nominated qualified persons, the Committee will propose the new directors and senior executives to the Board of Directors Meeting for consideration and/or proposing to the Shareholders’ Meeting for approval, as the case may be.

(5) In case of the appointment of directors to replace the vacant positions for reasons other than rotation of office, the Nomination and Remuneration Committee shall select persons who are fully qualified in accordance with the determined criteria to propose to the Board of Directors Meeting to appoint a replacement position in the next Board of Directors Meeting unless the term of the director is less than two months. The person who is appointed to the position in such case shall remain in the position for only the remaining term of the vacating director

Did Any Independent Director Have a Business or Professional Relationship?

No

Evaluation of Board & Subcommittee Performance

Criteria for Evaluating Board Performance

Performance Assessment of the Board of Directors and Sub-Committees

To ensure that the governance, control and management fully comply with the corporate Governance principles and to monitor and assess the result against the objectives and goals, the Company set a policy for the Board of Directors, Sub-Committees and the Chief Executive Officer to take the performance appraisal at least once a year. The assessment results will provide the Board of Directors, Sub-Committees and the Chief Executive Officer with significant information and opportunity to review their performance, issues and problems in the past year. This will enhance the effectiveness of the performance of the Board of Directors, Sub-Committees and the Chief Executive Officer with the assessment process and criteria as follows:


The Company organizes performance appraisal of the Board of Directors and Sub-Committees on a yearly basis. The appraisal covers three areas as follows:

(1) Self-assessment of the Board of Directors and Sub-Committees

(2) Individual self-assessment of the Board of Directors and Sub-Committees

(3) Individual assessment of the Board of Directors (assessing other members)


Operating Performance Assessment Process

(1) The Nomination and Remuneration Committee considers and set policy and scoring criteria of each key item based on the assessment form.

(2) The Company Secretary Office will submit the performance assessment form to all Directors for both group and individual assessment.

(3) The Board of Directors sends back the form to the Company Secretary Office who collects and summarizes the assessment results, and reports to the Nomination and Remuneration Committee and the Board of Directors in the first Board of Directors’ Meeting of the year. Moreover, for various recommendations received from the performance evaluation of the Company's board and sub-committees, the Company will adjust enhance the effectiveness of the board and sub-committees, aiming to maximize the benefits in conducting business and overseeing the Company's operations in the future.


Scoring Criteria and Assessment Summary


Score (%) Level

85 - 100 Excellence

75 - 84 Very Good

65 - 74 Good

50 - 64 Fair

Below 50 Need Urgent Improvement

Evaluation of Board Performance in the Past Year

The Board of Directors’ performance assessment results are as follows: Result Score (%)

1. Individual assessment of the Board of Directors (self-assessment) Y.2021/96.32 Y.2022/98.10 Y.2023/97.95 Y.2024/98.42

2. Individual assessment of the Board of Directors (assessing others) Y.2021/98.77 Y.2022/99.42 Y.2023/99.11 Y.2024/99.41

3. Assessment of the Board of Directors (group assessment) Y.2021/96.94 Y.2022/99.01 Y.2023/98.66 Y.2024/99.27

Evaluation Results

Evaluated BodyGroup — Carried Out?Group — Grade / Average ScoreGroup — Grade / Full ScoreIndividual (Self-Assessment) — Carried Out?Individual (Self-Assessment) — Grade / Average ScoreIndividual (Self-Assessment) — Grade / Full ScoreCross (Assessing Other Directors) — Carried Out?Cross (Assessing Other Directors) — Grade / Average ScoreCross (Assessing Other Directors) — Grade / Full Score
Board Of DirectorY99.27100.00Y98.42100.00Y99.41100.00
Executive CommitteeY97.14100.00Y97.22100.00N
Audit CommitteeY100.00100.00Y99.07100.00N
Other SubcommitteeY99.54100.00Y98.15100.00N
Other SubcommitteeY100.00100.00Y99.07100.00N

Subcommittees

Subcommittees

Results of the Subcommittee's Duty Performance

The Nomination and Remuneration Committee is appointed by the Board of Directors and comprises three members, all of whom meet the qualifications prescribed by applicable laws and relevant regulations. The committee is structured as follows: Two independent directors and One non-executive director. In 2024, the Nomination and Remuneration Committee convened a total of two hybrid-format meetings and carried out its duties in accordance with its charter, as well as other relevant responsibilities. A summary of its key activities as follows:

1. Monitored and followed up the implementation of the Succession Plan of senior executives, the Chief Executive Officer, Deputy Managing Directors and Assistant Managing Directors.

2. Agreed to amend the Nomination and Remuneration Committee Charter, Section 6, regarding meetings, to be in line with the Company's regulations, by specifying that meeting notices must be sent to the Nomination and Remuneration Committee at least 3 days in advance, and meetings can be held via electronic media.

3. Approve the criteria and performance evaluation of the Company's directors and subcommittees and present them to the Board of Directors for consideration and approval.

4. Consider and approve the assessment results of the executive committee's performance and compensation for the year 2023 to be presented to the Board of Directors for consideration and approval, including considering the criteria for evaluating the performance and compensation of the executive committee for the next year.

5. Recruit and nominate the directors who have left their positions by rotation to return to their positions as independent directors, directors, and subcommittees for another term, as well as nominate the Company’s executive directors from outside who have left their positions by rotation to return to the Company’s directors for another term. In addition, an additional director has been selected to support the increasing growth rate, promote operational efficiency, and provide both short-term and long-term returns. Dr. Tanai Charinsarn has been nominated as an independent director, executive director, and director of corporate governance and sustainable business development. In selecting directors, the selection process considered appropriate qualifications that are complete according to relevant laws and regulations, without prohibited characteristics, with ethics, knowledge, and ability, with “very good” performance results, capable of creating benefits for the Company, and ready to devote time to perform duties to the fullest extent, and presented to the Board of Directors and/or the annual general meeting of shareholders for consideration and approval.

6. Consider, screen and propose the remuneration of the Board of Directors, the Executive Committee, the Audit Committee, the Nomination and Remuneration Committee, and the Corporate Governance and Sustainable Business Development Committee for the year 2024 in accordance with the Company's criteria and various appropriateness, as well as the duties, responsibilities, continuous growth of the Company, challenging goals, and the addition of 1 new director, which is comparable to companies in the same industry and of a similar size, meeting plans, performance results, and bonuses for the Company's directors, excluding executive directors, and present them to the Board of Directors and/or the general meeting of shareholders for consideration and approval.


The Nomination and Remuneration Committee has performed its duties as assigned with care and prudence by taking into consideration economic situations and the Company’s revenue growth with a commitment to creating value and acting in the best interests of shareholders and other stakeholders. The Nomination and Remuneration Committee has reported its performance results to the Board of Directors on a quarterly basis.

The Board of Directors of Praram 9 Hospital Public Company Limited has appointed a Corporate Governance and Sustainability Development Committee, or the “Corporate Governance Committee” to support and promote the proper implementation of internal and external organizational activities. The committee is tasked with ensuring ethics and compliance with international corporate governance standards and relevant requirements. Currently, the committee consists of three members, including 2 independent directors and 1 executive director. In the year 2024, the Corporate Governance Committee held a total of 2 meetings in a hybrid format and performed its duties as assigned in accordance with the details specified in the charter, summarizing as follows:

1. Approval of the 2024 Corporate Sustainability Action Plan The Company has adopted an ESG-driven approach, encompassing environmental, social, corporate governance, and economic dimensions, along with human rights considerations, to ensure a balanced and sustainable healthcare environment. The committee has endorsed several key initiatives, including: Expanding the Smart Checkup project into a fully integrated Smart Hospital , Continuing the Happy Kidney and Happy Monk projects , Launching the ESG DNA program, a sustainability training series for employees , Implementing Climate Change Management initiatives , Providing additional recommendations on new strategies and implementation methods to establish clear and practical sustainability guidelines.

2. Oversight and Monitoring of Compliance with Regulations and Best Practices The committee ensures that the Company adheres to relevant regulations, best practices, and the United Nations Sustainable Development Goals (SDGs) while continuously monitoring sustainability action plans and performance indicators.

3. Approval of the Renewal Process for the Thai Private Sector Collective Action Against Corruption (CAC) Certification Prior to submission for final approval by the Board of Directors.

4. Promotion of Anti-Corruption Training for Employees The committee has endorsed annual anti-corruption training conducted by external experts, including a mandatory post-training assessment, ensuring that employees meet the Company’s compliance standards.

5. Expansion of the Anti-Corruption Network The committee supports an initiative to invite customers, business partners, and stakeholders to join the Company’s Anti-Corruption Collaboration Program, reinforcing ethical business practices.

6. Approval of the Company’s Participation in the SET ESG Ratings Assessment and the SET Awards – Sustainability Excellence Category for 2024. The Company aims to maintain and improve its sustainability performance ranking.

7. Amendment of the Corporate Governance Committee Charter The committee approved revisions to Section 5: Scope of Authority and Responsibilities, aligning with the Stock Exchange of Thailand’s (SET) 2024 Sustainability Assessment Framework. This amendment clarifies the committee’s role in overseeing climate-related risks and opportunities before submission to the Board of Directors for approval.

8. Discussions on FTSE Russell ESG Scores. The committee exchanged insights on the new sustainability assessment framework by the Stock Exchange of Thailand, which is expected to replace the current SET ESG Ratings methodology for listed companies.

9. Corporate Governance Policy Review. The committee reviewed and reinforced policies on corporate governance, transparency, and accountability, ensuring alignment with best practices. The committee will also monitor and promote adherence to corporate governance principles before submitting the policies for Board approval.

10. Scheduling of the 2025 Corporate Governance and Sustainable Business Development Committee Meetings. The committee has pre-scheduled meetings for the upcoming year to ensure structured oversight and strategic alignment.


To achieve the next milestone, the Corporate Governance and Sustainability Development Committee will continue to be committed to its intention and support the Company’s business operations to ensure that its services continuously meet the needs of clients and related stakeholders for their best interest and that the Hospital sustainably earns trust.


The Corporate Governance and Sustainable Business Development Committee remains committed to advancing sustainable development initiatives at PR9, ensuring continued trust and recognition while reinforcing the hospital’s long-term sustainability and growth.

Meeting Attendance & Remuneration

Justification for Directors' Non-Attendance

Dr. Prasert Trairatvorakul Requested a leave of absence to run an important errand.

Types of Remuneration of the Board of Directors

Remuneration Determination

To ensure the process of determining remuneration and other benefits of the Board of Directors, subcommittees and the Chief Executive Officer is transparent and in compliance with the principles of good corporate governance and in alignment with the Company’s long-term strategy and goals and the components of remuneration and other benefits are appropriate and sufficient to motivate and retain qualified personnel, the Company has therefore formulated a policy and criteria for determining remuneration and other benefits of the Board of Directors, subcommittees and the Chief Executive Officer as follows:

1. Process of determining remuneration and other benefits

The Nomination and Remuneration Committee shall consider and determine remuneration and other benefits of the Board of Directors, Sub-Committees and the Chief Executive Officer and shall proceed as follows:

(1) Remuneration and other benefits of the Board of Directors and subcommittees shall be proposed to the Board of Directors for consideration within the framework approved by the Shareholders’ Meeting.

(2) Remuneration and other benefits of the Chief Executive Officer shall be proposed to the Board of Directors for approval.

2. Guidelines for determining remuneration and other benefits

(1) Remuneration and other benefits of the Board of Directors and subcommittees

The determination of remuneration of the Board of Directors and Sub-Committees shall be based on the obligations of directors; which must be in compliance with the fiduciary duty principle, responsibilities, dedication, values received from the performance of duties of directors as well as incentives for qualified directors who are appropriate for the needs of the Company. Such is done by determining the components of remuneration for directors as follows:

(1.1) Retainer fee paid to non-executive directors on a monthly basis, whether or not there is a Board of Directors Meeting, by taking into account the following factors:

• Industry practice guidelines

• Operating results and business size

• Knowledge, competence and experience of directors to be recruited or in need of the Company at that moment.

(1.2) Attendance fee paid to directors attending each meeting paid only to the directors who attended the meeting, which is divided into

• Attendance fee of the Chairman of the Board of Directors and the Chairman of the subcommittees • Attendance fee of directors and subcommittees

(1.3) Incentive fee is a special remuneration paid to the directors once a year, by considering the values created for shareholders such as the Company’s profits or dividends paid to shareholders, but will not focus on the Company’s short-term performance.

(1.4) Other benefits (both monetary and non-monetary forms) which may be considered as an exact amount at a fixed rate or a special criterion and will be paid from time to time or to be effective until the Shareholders’ Meeting has resolved to change otherwise.

Remuneration or Benefits Payable to the Board

MetricAmount (Baht)
Remunerations or benefits pending payment to the board of directors over the past year (baht)0

Supervision of Subsidiaries & Associated Companies

Does the Company Have Subsidiaries or Associated Companies?

No

Is There a Mechanism for Overseeing Subsidiaries and Associated Companies?

No

Mechanism for Overseeing Management of Subsidiaries

As of 31 December 2024, the Company does not have investment in subsidiaries or associates or an investment plan in the near future, and, therefore; has no policy on investment and supervision of subsidiaries and associates. In case it has a plan to invest in subsidiaries or associates in the future, it will then prepare an investment policy and the policy on supervision of subsidiaries and associates that are complete and in accordance with the principle and practice guidelines.

Board Duty Performance — Overview

Board Duty Performance — Overall Description

8.1.1 Nomination, Development and Appraisal of the Committee Performance

1) Independent Director

Of the total number of members of the Board of Directors, at least one third or no less than three persons must be independent directors, according to the Company’s Good Corporate Governance and Business Code of Conduct Handbook. All independent directors shall be knowledgeable, competent and qualified as prescribed by the laws, by being able to independently express opinions in the meeting, regularly attend the meetings and have adequate access to other financial and business information to be able to express opinions independently, maintain the benefits of related persons and prevent conflicts of interest between the Company and directors, executives or majority shareholders or other companies that have the same group of directors, executives or majority shareholders. Moreover, independent directors shall report their independence once appointed and on yearly basis, which will be disclosed in the Annual Report and notified to the Company for acknowledgement of changes.

The Company has established the following qualifications of independent director:

(1) Holding no more than one percent of total voting shares of the Company, its parent company, subsidiaries, associated company, major shareholders or controlling persons, inclusive of the shares held by related persons of such independent director.

(2) Not being or used to be an executive director, employee, staff, advisor with regular salary, or controlling person of the Company, its parent company, subsidiary, associated company, subsidiary of the same level, major shareholder or controlling person unless the person has retired from having such characteristics for at least two years prior to the appointment as independent director. Such prohibited characteristics, however, do not include the case that the independent director used to be a government official or advisor of a government agency which is a major shareholder or controlling person of the Company.

(3) Not being related, whether by blood or legal registration as father, mother, spouse, sibling and child, including spouse of the offspring of other directors, executives, major shareholders, controlling parties, or persons who will be nominated as directors, executives, or controlling parties of the Company or subsidiary.

(4) Not having or never had any relationship with the Company, its parent company, subsidiary, associated company, major shareholder or controlling person, in the manner that may prevent the person to have independent judgement. The person should not currently be or never be a significant shareholder or controlling person of any person having a business relationship with the Company, its parent company, subsidiary, associated company, major shareholder or controlling person, unless the person has retired from having such characteristics at least two years before the appointment as an independent director.

(5) Not being or having never been the auditor of the Company, its parent company, subsidiary, associated company, major shareholder or controlling person and not being a significant shareholder, controlling person, or partner of an audit firm which employs auditors of the Company, its parent company, subsidiary, associated company, major shareholder or controlling person; unless the person has retired from having such characteristics at least two years before appointment as an independent director.

(6) Not providing or having never provided professional services, legal consulting, nor financial consulting services and received fees exceeding two million Baht per year from the Company, its parent company, subsidiary, associated company, major shareholder or controlling person, and not being a significant shareholder, controlling person or partners of the such services providers unless the person has retired from having such characteristics at least two years before appointment as an independent director.

(7) Not being a director appointed as a proxy of the Company’s director, major shareholder, or a shareholder with relationship with a major shareholder

(8) Not undertaking any business of the same nature and in competition with the business of the Company or the Company’s subsidiary, or not being a significant partner in a partnership nor an executive director, employee, staff, advisor with regular salary or holding shares exceeding one percent of the total number of shares with voting rights of another company which operates a business of the same nature and in competition with the Company or its subsidiary

(9) Not possessing any other characteristics that prevent the ability to independently express opinions on the Company’s business operations.


The Company’s three Independent Directors, as of 31 December 2024 are as follows :

1. Mr. Kanit Patsaman Independent Director

2. Emeritus professor Wg.Cdr. Dr.Sirintara Singhara na ayudhaya Independent Director

3. Mr. Piset Chiyasak Independent Director

4. Dr. Tanai Charinsarn Independent Director


One of the Company’s Independent Director, Emeritus professor Wg. Cdr. Dr. Sirintara Singhara Na Ayudhaya (“Emeritus professor Wg. Cdr. Dr. Sirintara”) (Member of the Audit Committee), who is a medical consultant, does not perform medical examination, but perform medical operations or procedures on a case-by-case basis.

Audit Committee Duty Performance

Results of the Audit Committee's Duty Performance in the Past Year

The Audit Committee of Praram 9 Hospital Public Company Limited comprises three Independent Directors who have knowledge, capabilities, experience and required qualifications in accordance with the Audit Committee Charter and the notifications of the Stock Exchange of Thailand, namely Mr. Kanit Patsaman, Chairman of the Audit Committee and committee members consisting of Emeritus professor Wg. Cdr. Dr. Sirintara Singhara Na Ayudhaya and Mr. Piset Chiyasak. In 2024, the Audit Committee independently performed its duties within the scope of duties and responsibilities stipulated in the Audit Committee Charter approved by the Board of Directors. The Audit Committee held four meetings with the management, the external auditor and the internal auditor and a meeting with the external auditor and the internal auditor without the presence of the management, the details of which are as above


The key performance areas and opinions made by the Audit Committee as well as reports on various matters submitted to the Board of Directors as follows:

1. Review of Financial Statements The Audit Committee reviewed the Company’s quarterly and annual financial statements which had been reviewed and audited by the certified public accountant that such financial statements had been prepared in accordance with generally-accepted accounting standards and that the information disclosed in financial statements was accurate, complete and reliable. The Audit Committee also invited the certified public accountant and executives responsible for preparing financial statements to attend every meeting where there was an agenda to consider the financial statements before submitting to the Board of Directors for approval. The Audit Committee was of the opinions and certain that the financial statements had been accurately prepared in accordance with generally-accepted accounting standards and adequately disclosed in the Notes to the Financial Statements. In addition, the Audit Committee held a meeting with the external auditor without the presence of the management to enable free exchange of information and opinions.

2. Assessment and review of internal control system The Audit Committee reviewed the internal control system taking into account the audit report from the auditor, the report from the internal audit and the Risk Management Working Group and the adequacy of the internal control system in accordance with the guidelines set by the Securities and Exchange Commission (SEC). The Audit Committee regularly reported the assessment results and its opinions to the Board of Directors and the management to ensure that the Company has put in place an effective internal control system that is appropriate and sufficient for its business operations to enable it to achieve operational efficiency and effectiveness, prevent and reduce risks and possible damages, have accurate and reliable financial reports and continuously develop and improve its internal control system.

3. Internal control Oversight The Audit Committee approved hiring Accounting Revolution Company Limited with Mrs. Sasivimon Suksai as Head of Internal Audit, whose service proposal had passed the assessment and was benchmarked against other companies’ to independently perform duties in accordance with the annual audit plan that had been approved by the Audit Committee. The Audit Committee has continuously monitored and followed up on the implementation in accordance with the observations made by the Internal Auditor in the audit reports which the Audit Committee had considered and provided its opinions. The consideration and approval of the appointment, removal and transfer of the position and determination of the remuneration of the Head of Internal Audit shall be considered and approved by the Audit Committee. In addition, the Audit Committee held meetings with the Head of Internal Audit without the presence of the management to enable free exchange of information and opinions.

4. Supervision of Compliance with the Code of Conduct, Laws and Policies The Audit Committee reviewed the corporate governance procedures and process of receiving complaints in terms of quality of service, ethics, prevention and whistleblowing process or reports of fraud and corruption made by whistleblowers by hearing and making its opinions based on the reports of the Quality Department, the unit directly responsible for the reports of Risk Management Working Group and internal auditors. The Audit Committee acknowledged the changes in the laws on securities and exchange and those relevant to the Company’ s business operations and reviewed the Company’s operations to ensure compliance with the Code of Conduct, relevant laws and rules and regulations and the Company’ s readiness for continuous changes.

5. Risk management review The Audit Committee reviewed and made its opinions on the Company’s enterprise risks and risk management plan and regularly followed up on results reporting of the Risk Management Working Group on a quarterly basis. In addition, the Audit Committee supported the analysis of risks relating to the Company’s sustainability from its three dimensions: ESG (Environment, Social and Governance) and submitted a risk analysis and monitoring report to the Board of Directors, respectively.

6. Consideration of Connected Transactions or those with potential conflicts of interest. The Audit Committee reviewed and made its opinions on the necessity and rationality of connected transactions or those with potential conflicts of interest as well as contracts, agreements and main conditions, including adequate and complete disclosure of information in compliance with the requirements of the Stock Exchange of Thailand.

7. Consideration of the selection and appointment of the Auditor Taking into consideration the Auditor’s performance, knowledge, capabilities, understanding of the Company’s nature of business, quality of services and qualifications as well as appropriateness of the audit fees which had been compared with the proposals of other audit offices, the Audit Committee deemed it appropriate to appoint EY Office Company Limited as the Company’s annual auditor and propose annual audit fees to the Board of Directors and the Shareholders’ Meeting for approval.

8. Performance assessment and Charter review The Audit Committee considered both collective and Individual self-assessment, reviewed the Audit Committee Charter by comparing the scope of duties and responsibilities with the Audit Committee Handbook prepared by the Securities and Exchange Commission (SEC) and proposed it to the Board of Directors for approval.


The Audit Committee performed its duties and responsibilities in accordance with the Audit Committee Charter and as delegated by the Board of Directors with prudence and to the best of its abilities. The Audit Committee was of the opinion that the Company’s financial reports and information disclosure were adequate, appropriate and reliable in accordance with generally-accepted accounting standards and has put in place effective internal control and risk management systems which were appropriate and sufficient for its operations. The Company also adequately disclosed its connected transactions and information, adhered to the corporate governance principles and continuously developed and enhanced the quality of its internal control system.

Executive Committee Duty Performance

Results of the Executive Committee's Duty Performance in the Past Year

In 2024, Praram 9 Hospital Public Company Limited held 12 Executive Committee’s Meetings and managed significant matters as follows:

1. Business Growth Strategy. The hospital is committed to becoming a modern healthcare hub, offering the best and most cost-effective medical services, prevention, and healthcare solutions. This commitment is driven by four core strategic pillars: Global Standard , World-Class Hospitality , Efficiency with Collaboration , Digital Transformation. The hospital continues to upgrade its medical centers to meet world-class standards, particularly in its Kidney Transplant Institute, Cardiovascular Institute, and Orthopedic Center was ranked No. 1 in Thailand by Newsweek. And research study from the Kidney Transplant Institute was published in Nature, one of the world's most prestigious medical journals. The Cardiovascular Institute has successfully implemented complex minimally invasive heart valve replacement procedures (TAVI), requiring advanced medical technology and highly specialized teams. These developments have positioned Praram 9 Hospital as a leading medical institution capable of handling complex cases for both domestic and international patients.

2. Facility Upgrades: Renovation of International Center and Main Hall (1st floor, Building A) to accommodate increasing foreign patient demand. Expansion of Outpatient Services (2nd floor, Building A) to manage the growing patient volume. Ongoing design and planning for MRI facilities (1st floor), 12th and 14th floors of Building A, and 16th floor of Building B. Plans to construct staff and nurse accommodation to support the hospital’s future expansion.

3. Digital Strategy : Advancing towards a fully digital hospital, enhancing patient services through a patient-centric approach. Enhancing service efficiency before, during, and after hospital visits through the Smart Hospital Project. Achieving international recognition with the "Digital Transformation Initiative of the Year" award at the Healthcare Asia Awards 2024 in Singapore, a prestigious event recognizing excellence in the Asian healthcare industry.

4. Brand Recognition : Ranked 3rd among Thailand’s most trusted private hospitals (Thailand’s Most Admired Company 2023-2024) by BrandAge magazine. Ranked 9th among all hospitals in Thailand, including public and private hospitals. Received the "Creativity and Innovation Award" at the Muang Thai Life Assurance Hospital Awards, recognizing continuous innovation in patient care for medium-sized hospitals. Continuous facility enhancements to create a modern, comfortable, and aesthetically pleasing environment, enhancing patient satisfaction and positive word-of-mouth recommendations.

5. Social Contributions

- Donated a mobile mammography unit worth THB 18 million to Tha Wung Hospital, Lopburi Province, for breast cancer screening and early detection.

- Received an honorary plaque for emergency assistance in facilitating the emergency landing of Singapore Airlines Flight SQ321 at Suvarnabhumi Airport, following severe turbulence.

- Launched the “Dispose E-Waste Properly for a Better Environment” campaign, raising awareness about proper disposal of electronic waste, which contains hazardous heavy metals that can harm the environment and public health.

6. Recognition as a Leading Listed Company on the Stock Exchange of Thailand (SET) The hospital achieved top-tier performance across four key governance and sustainability assessments:

- 5-Star CGR Rating 2024 – Thai Institute of Directors (IOD).

- AAA ESG Rating 2024 – SET’s highest sustainability rating in the Service sector.

- SET Awards 2024: Sustainability Excellence – Highly Commended Sustainability Award.

- 5-Star AGM Checklist 2024 – Thai Investors Association (TIA).

7. Sustainability and Transparency Recognition. Received the Sustainability Disclosure Recognition 2024, an award for outstanding sustainability reporting, reflecting the hospital’s commitment to transparency, sustainable business growth, and stakeholder engagement. Recognized for its balanced sustainability strategy, integrating environmental, social, and corporate governance (ESG) principles, following the Sustainable Development Framework by the Thaipat Institute.


In 2025, the hospital will focus on expanding its medical excellence in: Neurology and Neurosurgery , Minimally Invasive Surgery , Diabetic Wound Care. To support this, Phyathai 9 Hospital is recruiting top-tier specialists and investing in state-of-the-art medical equipment, ensuring superior treatment outcomes and enhanced patient satisfaction. These initiatives will contribute to sustainable growth and further reinforce the hospital’s reputation as a leader in world-class healthcare services.

Contents